Kevin Finney
Vorstandsvorsitzender bei Autobahn Therapeutics, Inc.
Profil
Kevin Finney is currently the Chairman & Chief Executive Officer at Autobahn Therapeutics, Inc. He is also the Vice Chairman at Eirion Therapeutics, Inc. Additionally, he holds the position of Chairman at Elsie Biotechnologies Inc. and Director at TARIS BioMedical LLC.
Previously, he served as the President, Chief Operating Officer & Director at Abide Therapeutics, Inc. Mr. Finney completed his undergraduate degree at The California State University and holds an MBA from Pepperdine University.
Aktive Positionen von Kevin Finney
Unternehmen | Position | Beginn |
---|---|---|
TARIS BioMedical LLC
TARIS BioMedical LLC Pharmaceuticals: MajorHealth Technology TARIS BioMedical LLC operates as a clinical-stage pharmaceutical company. It specializes in urology, continuous local dosing, bladder diseases, oncology, voiding dysfunction. The company was founded by Robert S. Langer Jr., Christine Bunt, and Michael J. Cima in 2008 and is headquartered in Lexington, MA. | Direktor/Vorstandsmitglied | 27.10.2015 |
Eirion Therapeutics, Inc.
Eirion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Eirion Therapeutics, Inc. is a clinical stage biopharmaceutical company that is developing prescription products for aesthetic dermatology. The company is based in Woburn, MA. The company has a pipeline of products that focus on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. Eirion plans to pursue additional indications that address other major unmet clinical needs for physicians and their patients. The company was founded in 2016. Jonathan T. Edelson has been the CEO of the company since 2016. | Direktor/Vorstandsmitglied | 01.01.2016 |
Autobahn Therapeutics, Inc.
Autobahn Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Autobahn Therapeutics, Inc. is a thyromimetics drug discovery company. It serves patients with neurodegenerative disorders. The company is headquartered in San Diego, CA. | Vorstandsvorsitzender | 09.06.2020 |
Elsie Biotechnologies Inc.
Elsie Biotechnologies Inc. BiotechnologyHealth Technology Elsie Biotechnologies Inc. is a private company located in California that is focused on utilizing RNA therapeutics to treat diseases that were previously considered undruggable. The American company's platform enables the synthesis, deconvolution, and delivery of homogeneous oligonucleotide therapeutics. The company was founded in 2021 by Philip E. Dawson and Phil Baran, and the CEO is Kyle Jenne. | Vorsitzender | - |
Ehemalige bekannte Positionen von Kevin Finney
Unternehmen | Position | Ende |
---|---|---|
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Präsident | - |
Ausbildung von Kevin Finney
The California State University | Undergraduate Degree |
Pepperdine University | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Private Unternehmen | 5 |
---|---|
TARIS BioMedical LLC
TARIS BioMedical LLC Pharmaceuticals: MajorHealth Technology TARIS BioMedical LLC operates as a clinical-stage pharmaceutical company. It specializes in urology, continuous local dosing, bladder diseases, oncology, voiding dysfunction. The company was founded by Robert S. Langer Jr., Christine Bunt, and Michael J. Cima in 2008 and is headquartered in Lexington, MA. | Health Technology |
Abide Therapeutics, Inc.
Abide Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Abide Therapeutics, Inc. develops medicines that target serine hydrolases. Its approach is to selectively block serine hydrolases, potentially expanding this class of commercially validated enzymes as targets in a range of indications. The firm has a technology platform that exploits a chemoproteomics approach to selectively target serine hydrolases and rapidly identify target lead pairs. The company was founded by Alan B. Ezekowitz, Dale Boger, John Kennedy Clarke, Benjamin F. Cravatt, Todd Jones, Keith F. Lenden, and Paul R. Schimmel in 2011 and is headquartered in San Diego, CA. | Health Technology |
Eirion Therapeutics, Inc.
Eirion Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Eirion Therapeutics, Inc. is a clinical stage biopharmaceutical company that is developing prescription products for aesthetic dermatology. The company is based in Woburn, MA. The company has a pipeline of products that focus on treatments for wrinkles, primary axillary hyperhidrosis, androgenic alopecia, and hair greying. Eirion plans to pursue additional indications that address other major unmet clinical needs for physicians and their patients. The company was founded in 2016. Jonathan T. Edelson has been the CEO of the company since 2016. | Health Technology |
Autobahn Therapeutics, Inc.
Autobahn Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Autobahn Therapeutics, Inc. is a thyromimetics drug discovery company. It serves patients with neurodegenerative disorders. The company is headquartered in San Diego, CA. | Commercial Services |
Elsie Biotechnologies Inc.
Elsie Biotechnologies Inc. BiotechnologyHealth Technology Elsie Biotechnologies Inc. is a private company located in California that is focused on utilizing RNA therapeutics to treat diseases that were previously considered undruggable. The American company's platform enables the synthesis, deconvolution, and delivery of homogeneous oligonucleotide therapeutics. The company was founded in 2021 by Philip E. Dawson and Phil Baran, and the CEO is Kyle Jenne. | Health Technology |